Latest news with #FahedAlMarzooqi
Al Etihad
25-04-2025
- Health
- Al Etihad
Department of Health – Abu Dhabi advances precision medicine for Alzheimer's
25 Apr 2025 14:20 The Department of Health - Abu Dhabi (DoH), in collaboration with M42 Biogenix Lab, has taken a groundbreaking step in personalised healthcare by integrating APOE E4 genetic testing into its pharmacogenomics (PGx) first-of-its-kind innovative approach in the region ensures that healthcare providers can assess a patient's genetic risk and personalise Alzheimer's treatments to ensure safer and more effective disease is a progressive neurological condition characterised by memory loss, cognitive decline and behavioural changes. According to the World Health Organization, Alzheimer's is the leading cause of dementia worldwide. Globally, there are over 10 million new cases of dementia each year, equating to one new case every 3.2 inclusion of the APOE E4 genotyping in the pharmacogenomics reports is a result of collaboration between The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and M42's Biogenix Lab. It represents a significant milestone in precision treated with anti-amyloid monoclonal antibodies, as one of the therapeutic options, Alzheimer's patients with two copies of APOE E4 may experience severe side effects, such as brain swelling or bleeding. Therefore, by identifying these genetic risks, clinicians can tailor Alzheimer's treatment plans for the individual, ensuring the best outcomes while minimising adverse reactions that can be Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health - Abu Dhabi, said: 'The inclusion of APOE E4 genotyping in PGx report reflects our commitment to providing the best-in-class care for our communities through genetic profiling and precision therapies. This re-affirms Abu Dhabi's position as a global leader in healthcare innovation, driven by genomics-based healthcare solutions. Our goal is to provide clinicians with the most up-to-date and actionable genetic insights. These insights can be integrated into treatment plans, especially for therapies involving anti-amyloid monoclonal antibodies, to ensure safer and more effective care.'The pharmacogenomics reports initiative is part of the Emirati Genome Programme (EGP), which is building a comprehensive genetic database to support tailored treatments for EGP participants. PGx reports are securely available to all physicians in Abu Dhabi through Malaffi, DoH's health information a transformative milestone, 160,000 PGx reports are now available, a scale that surpasses many population genomics application programmes globally. This achievement will set a new standard for population genomics. Dr Fahed Al Marzooqi, Chief Executive Officer of Integrated Health Solutions at M42, said, 'The integration of pharmacogenomics into clinical care marks a transformative step towards precision medicine in Abu Dhabi. By embedding these insights directly into patient records, we are equipping healthcare providers with actionable data to enhance treatment safety and efficacy. This initiative, led by the Department of Health – Abu Dhabi, is made possible through M42's advanced health technology infrastructure, ensuring that every patient receives care that is tailored to their unique genetic makeup." "This milestone reaffirms Abu Dhabi's commitment to innovation in medicine and to putting patients at the centre of healthcare transformation. Currently, the reports are available for patients with specific conditions, including cancer, mental health disorders, respiratory illnesses, gastrointestinal issues, cardiovascular diseases, and infectious diseases, neurological diseases, pain management and now Alzheimer's," Al Marzooqi said. The Department of Health - Abu Dhabi and M42's Biogenix Lab are committed to regularly updating pharmacogenomics tools to reflect the latest scientific developments, ensuring continuous improvements in patient care.
Al Etihad
16-04-2025
- Business
- Al Etihad
M42 announces strategic investment, partnership with leading biotech Juvenescence
16 Apr 2025 17:16 ABU DHABI (ALETIHAD)M42, a global health leader powered by artificial intelligence (AI), technology, and genomics, on Wednesday announced a strategic investment and partnership in longevity biotech leader Juvenescence. The announcement was made during Abu Dhabi Global Health Week (ADGHW), a year-round 'always-on' platform with a proactive approach centred around preventive, personalised, and holistic care, which is being held from April 15 to 17 at ADNEC, where M42 serves as a Foundational Partner for the second consecutive year. As part of this investment, M42 and Juvenescence will form a strategic partnership to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening strategic partnership and investment underlines M42's commitment to advancing its capabilities in drug discovery and development, following the creation of its Integrated Health Solutions and Life Sciences platforms under its new, recently announced operating structure. Leveraging M42's deep expertise in genomics, biobanking, and clinical trial infrastructure alongside Juvenescence's cutting-edge AI-enabled discovery technology and extensive drug development expertise, this collaboration will drive breakthroughs in life sciences research, enhance disease understanding, and enable fast-tracking of clinical well as identifying novel drug targets and therapeutics, the partnership will explore collaboration in R&D with leading academic and research organisations globally while supporting the development of M42's biotechnology strategy in Abu Dhabi. A joint steering committee comprised of senior executives from both companies will oversee the execution of this Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, said, "With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi's push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges. With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it's about impact – on lives, on science, and on the future of health.'Dr Fahed Al Marzooqi, Chief Executive Officer of M42's Integrated Health Solutions platform and Acting Chief Executive Officer of M42's AI Life Sciences platform, added, 'Our partnership with Juvenescence is a crucial step toward redefining healthcare through AI-driven drug discovery and biotechnology. By uniting AI innovation with biotech expertise, we're not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress—delivering transformative therapies from Abu Dhabi to the world.'Dr. Richard Marshall, Chief Executive Officer at Juvenescence, said, 'We are delighted to be working together with M42. This powerful partnership will combine M42's expertise in AI, technology, and genomics with Juvenescence's unrivalled ability to discover and develop innovative drugs for age-related disease. Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the healthspan of patients globally.'The collaboration will see Juvenescence's team of globally recognised scientists and industry leaders - with more than 150 years of cumulative experience in drug discovery and development - work with M42 to build its own innovative therapeutics partnering with Juvenescence, M42 is building on its genomics expertise developed in collaboration with the Department of Health Abu Dhabi (DoH) to further drive advancements in disease understanding and precision medicine. M42's Omics Center of Excellence - the largest outside the U.S. - supports the Emirati Genome Project (EGP), which has already sequenced over 800,000 whole genomes and has a goal of sequencing one million local M42's Abu Dhabi Biobank (ADBB) has stored over 900,000 samples, a repository that will be an invaluable resource for future biomedical research in the UAE and beyond. The partnership aligns with Abu Dhabi's broader vision to become a world-class destination for health innovation and to build a life sciences hub as part of its economic diversification agenda.
Zawya
16-04-2025
- Business
- Zawya
M42 announces strategic investment, partnership with leading biotech Juvenescence
M42, a global health leader powered by artificial intelligence (AI), technology and genomics, today announces a strategic investment and partnership in longevity biotech leader Juvenescence. The announcement was made during Abu Dhabi Global Health Week (ADGHW), a year-round 'always-on' platform with a proactive approach centred around preventive, personalised, and holistic care, which is being held from 15 to 17 April at ADNEC, where M42 serves as a Foundational Partner for the second consecutive year. As part of this investment, M42 and Juvenescence will form a strategic partnership to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening diseases. The strategic partnership and investment underlines M42's commitment to advancing its capabilities in drug discovery and development following the creation of its Integrated Health Solutions and Life Sciences platforms under its new operating structure announced recently. Leveraging M42's deep expertise in genomics, biobanking, and clinical trial infrastructure alongside Juvenescence's cutting-edge AI-enabled discovery technology and extensive drug development expertise, this collaboration will drive breakthroughs in life sciences research, enhance disease understanding, and enable fast-tracking of clinical trials. As well as identifying novel drug targets and therapeutics, the partnership will explore collaboration in R&D with leading academic and research organizations globally and support the development of M42's biotechnology strategy in Abu Dhabi. A Joint Steering Committee comprised of senior executives from both companies will oversee the execution of this partnership. Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, said, "With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi's push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges. With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it's about impact – on lives, on science and on the future of health.' Dr Fahed Al Marzooqi, Chief Executive Officer of M42's Integrated Health Solutions platform and Acting Chief Executive Officer of M42's AI Life Sciences platform, added, 'Our partnership with Juvenescence is a crucial step toward redefining healthcare through AI-driven drug discovery and biotechnology. By uniting AI innovation with biotech expertise, we're not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress—delivering transformative therapies from Abu Dhabi to the world.' Dr. Richard Marshall, Chief Executive Officer at Juvenescence, said, 'We are delighted to be working together with M42. This powerful partnership will combine M42's expertise in AI, technology, and genomics with Juvenescence's unrivalled ability to discover and develop innovative drugs for age-related disease. Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the healthspan of patients globally.' The collaboration will see Juvenescence's team of globally recognized scientists and industry leaders - with more than 150 years of cumulative experience in drug discovery and development* work with M42 to build its own innovative therapeutics pipeline. By partnering with Juvenescence, M42 is building on its genomics expertise developed in collaboration with the Department of Health Abu Dhabi (DoH) to further drive advancements in disease understanding and precision medicine. M42's Omics Center of Excellence - the largest outside the U.S. - supports the Emirati Genome Project (EGP), which has already sequenced over 800,000 whole genomes and has a goal of sequencing one million local Emiratis. Additionally, M42's Abu Dhabi Biobank (ADBB) has stored over 900,000 samples, a repository that will be an invaluable resource for future biomedical research in the UAE and beyond. The partnership aligns with Abu Dhabi's broader vision to become a world-class destination for health innovation and to build a life sciences hub as part of its economic diversification agenda.
Zawya
16-04-2025
- Business
- Zawya
M42 announces strategic investment and partnership with leading biotech Juvenescence
M42 and Juvenescence will collaborate in drug discovery to develop a pipeline of innovative medicines to advance the prevention and treatment of diseases of high unmet need within UAE and globally and age-related diseases M42's strategic investment in Juvenescence will accelerate Juvenescence's clinical pipeline and drug development capabilities which underscores this collaboration Expansion of capabilities in AI-enabled therapeutics underlines Abu Dhabi's vision of becoming a global hub for AI-driven longevity science and next-generation drug development Abu Dhabi – M42, a global health leader powered by artificial intelligence (AI), technology and genomics, today announces a strategic investment and partnership in longevity biotech leader Juvenescence. The announcement was made during Abu Dhabi Global Health Week (ADGHW), a year-round 'always-on' platform with a proactive approach centred around preventive, personalised, and holistic care, which is being held from 15 to 17 April at ADNEC, where M42 serves as a Foundational Partner for the second consecutive year. As part of this investment, M42 and Juvenescence will form a strategic partnership to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening diseases. The strategic partnership and investment underlines M42's commitment to advancing its capabilities in drug discovery and development following the creation of its Integrated Health Solutions and Life Sciences platforms under its new operating structure announced recently. Leveraging M42's deep expertise in genomics, biobanking, and clinical trial infrastructure alongside Juvenescence's cutting-edge AI-enabled discovery technology and extensive drug development expertise, this collaboration will drive breakthroughs in life sciences research, enhance disease understanding, and enable fast-tracking of clinical trials. As well as identifying novel drug targets and therapeutics, the partnership will explore collaboration in R&D with leading academic and research organizations globally and support the development of M42's biotechnology strategy in Abu Dhabi. A Joint Steering Committee comprised of senior executives from both companies will oversee the execution of this partnership. Commenting on M42's investment and life sciences ambition, Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, said: "With this investment and partnership, M42 is taking great strides in reinforcing Abu Dhabi's push as a global nexus for AI-enabled therapeutics and biomedical innovation to tackle local and international health challenges. With Juvenescence, we are unlocking the potential of AI to transform the way we discover and deliver drugs, bringing innovative, life-changing therapies to patients worldwide. This is not just about innovation, it's about impact – on lives, on science and on the future of health.' Dr Fahed Al Marzooqi, Chief Executive Officer of M42's Integrated Health Solutions platform and Acting Chief Executive Officer of M42's AI Life Sciences platform, added: 'Our partnership with Juvenescence is a crucial step toward redefining healthcare through AI-driven drug discovery and biotechnology. By uniting AI innovation with biotech expertise, we're not only advancing the fight against age-related diseases but also building a global ecosystem that empowers prevention, precision, and progress—delivering transformative therapies from Abu Dhabi to the world.' Dr. Richard Marshall, Chief Executive Officer at Juvenescence, said: ' We are delighted to be working together with M42. This powerful partnership will combine M42's expertise in AI, technology, and genomics with Juvenescence's unrivalled ability to discover and develop innovative drugs for age-related disease. Our work together will enable the creation of a unique pipeline of innovative therapeutics that will have enormous potential to target the underlying causes of age-related disease and improve the healthspan of patients globally.' The collaboration will see Juvenescence's team of globally recognized scientists and industry leaders - with more than 150 years of cumulative experience in drug discovery and development* work with M42 to build its own innovative therapeutics pipeline. By partnering with Juvenescence, M42 is building on its genomics expertise developed in collaboration with the Department of Health Abu Dhabi (DoH) to further drive advancements in disease understanding and precision medicine. M42's Omics Center of Excellence - the largest outside the U.S. - supports the Emirati Genome Project (EGP), which has already sequenced over 800,000 whole genomes and has a goal of sequencing one million local Emiratis. Additionally, M42's Abu Dhabi Biobank (ADBB) has stored over 900,000 samples, a repository that will be an invaluable resource for future biomedical research in the UAE and beyond. The partnership aligns with Abu Dhabi's broader vision to become a world-class destination for health innovation and to build a life sciences hub as part of its economic diversification agenda. * In addition to Richard Marshall, CEO, the Juvenescence team consists of Jim Mellon, Deputy Chair and Founder of the Longevity Forum; Dr. Greg Bailey, Executive Chair; Dr. Declan Doogan, Director; Gillian Dines, Chief Scientific Officer; and, Dr. Steve Felstead, Chief Medical Officer. The Juvenescence development team have previously been instrumental in the approval of medicines totaling $30bn in peak annual sales. The track record of the co-founders (Jim, Greg and Declan), who have invested almost $100m in Juvenescence, have led two of the biggest 10 biopharma deals in the last decade including in May 2022 as Biohaven was acquired by Pfizer for USD $11.6 billion (having originally purchased 54% of Biohaven for USD $3.5 million). They were also involved in the initial financing for Medivation, which was later acquired by Pfizer for $14.3 billion, delivering over 200x returns. ABOUT M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanking, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi. For more information, visit: For media inquiries or interview opportunities, please contact: Mazar Masud Senior Director, Global Corporate Communications, M42 E: mmasud@ Asala Fadda Senior Manager, Group Marketing & Communications, M42 E: afadda@ ABOUT JUVENESCENCE Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat & prevent age-related diseases. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan - with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totalling $30bn in peak annual sales. Powered by an unrivaled drug development team, we leverage cutting-edge AI tools to unlock successful therapeutics. Our diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair. In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine. For more information, visit: About Abu Dhabi Global Health Week (ADGHW): ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care. Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being. ADGHW 2025 offers complimentary visitor passes that grant access to the event's Start Up Zone, live stage sessions and exhibition hall featuring 150 global leaders in health. For more information, visit
Mid East Info
31-01-2025
- Business
- Mid East Info
M42 and Hikma sign strategic MOU to enhance preventive and predictive cancer care in the UAE - Middle East Business News and Information
M42, a global health leader powered by artificial intelligence (AI), and Hikma Pharmaceuticals PLC (Hikma), announced the signing of a strategic memorandum of understanding (MOU), to accelerate the implementation of more precise, preventive and predictive cancer care programmes, utilising cutting-edge genomics screening technology. Under this agreement, Hikma and M42 will enhance their collaboration to promote the use of Shield™, a non-invasive laboratory-developed test (LDT) by Guardant Health Inc., for colorectal cancer (CRC) screening, aiming to improve screening adherence rates in the UAE. Shield™ is the first blood test to be approved by the US FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield in a manner similar to all other non-invasive methods recommended in screening guidelines. Dr. Fahed Al Marzooqi, Chief Executive Officer, Integrated Health Solutions, M42, said: 'At M42, we are committed to harnessing cutting-edge technologies to improve patient outcomes and empower health systems to deliver proactive care. This collaboration with Hikma reflects our dedication to supporting Abu Dhabi's broader efforts to lead in next-generation screening and health innovation. By integrating AI and genomics-driven solutions, we are redefining traditional healthcare models to create a healthier, more sustainable future for all.' Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: ' We are proud to sign this strategic partnership with M42 – a company that shares our commitment to innovation shaping the future of healthcare to improve patient outcomes. This important endeavour is focused on enhancing early disease detection, enabling more precise diagnoses, and facilitating more effective treatments, particularly in oncology and preventive care, which is aligned with our ambition of providing broader healthcare solutions focused on precision medicine.' Last year Hikma announced that it had signed an exclusive agreement with Guardant Health, Inc. for the commercialisation and marketing of Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumour mutation profiling across all solid cancers in the Middle East and North Africa (MENA). The agreement includes tests such as the US FDA approved Shield™ for colorectal cancer screening and early detection, as well as Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers. The introduction of the Shield™ test for colorectal cancer screening marks a transformative step in advancing precision and preventive healthcare across the region.
